Paraoxonase phenotype distribution in a healthy Iranian population
- PMID: 17651311
- DOI: 10.1111/j.1742-7843.2007.00080.x
Paraoxonase phenotype distribution in a healthy Iranian population
Abstract
Human serum paraoxonase (PON1) is a high-density lipoprotein-associated esterase that protects against organophosphate neurotoxicity, and is proposed to play a role in lipid metabolism and the onset of cardiovascular disease. In the present study, paraoxonase activities and phenotype distribution in serum of 132 healthy Iranian individuals aged 17-68 years were assessed using dual substrate method. In the study population, a wide interindividual variability (up to 15-fold) of paraoxonase activity was found. The mean of basal, salt-stimulated paraoxonase and arylesterase activities were 81.8 +/- 57 U/ml, 153.1 +/- 117.5 U/ml and 80.7 +/- 12.8 kU/l, respectively. The ratio of salt-stimulated paraoxonase activity to arylesterase activity was used for definition of phenotypes. Based on the observed ratios, three distinct phenotypes AA (low activity), AB (intermediate activity) and BB (high activity) were determined. The PON1 ratio varied from 0.5 to 6.8. The paraoxonase phenotype frequencies were approximately 48% (AA), 41% (AB) and 11% (BB). In this work, serum triglycerides had significant positive correlation (r = 0.334, P < 0.05) with paraoxonase activity, whereas high-density lipoprotein did not. No significant decrease in paraoxonase activity by smoking was observed. Age and sex had no influences on PON1 activities. In conclusion, the distribution of paraoxonase phenotypes in this Iranian population was trimodal and comparable to that of Caucasians from North America; however, overall enzyme activity was lower than that reported for Caucasians.
Similar articles
-
Levels of paraoxonase and arylesterase activities and malondialdehyde in workers exposed to ionizing radiation.Cell Biochem Funct. 2003 Dec;21(4):371-5. doi: 10.1002/cbf.1042. Cell Biochem Funct. 2003. PMID: 14624476
-
Paraoxonase/arylesterase in serum of patients with type II diabetes mellitus.Acta Pharm. 2006 Mar;56(1):59-68. Acta Pharm. 2006. PMID: 16613735
-
Serum paraoxonase activities in hemodialyzed uremic patients: cohort study.Croat Med J. 2001 Apr;42(2):146-50. Croat Med J. 2001. PMID: 11259735
-
Modulation of paraoxonase (PON1) activity.Biochem Pharmacol. 2005 Feb 15;69(4):541-50. doi: 10.1016/j.bcp.2004.08.027. Biochem Pharmacol. 2005. PMID: 15670573 Review.
-
Variation in paraoxonase-1 activity and atherosclerosis.Curr Opin Lipidol. 2009 Aug;20(4):265-74. doi: 10.1097/MOL.0b013e32832ec141. Curr Opin Lipidol. 2009. PMID: 19550323 Review.
Cited by
-
Paraoxonase1 genetic polymorphisms in a mixed ancestry African population.Mediators Inflamm. 2014;2014:217019. doi: 10.1155/2014/217019. Epub 2014 Nov 16. Mediators Inflamm. 2014. PMID: 25477710 Free PMC article.
-
The Relationship between Cancer and Paraoxonase 1.Antioxidants (Basel). 2022 Mar 31;11(4):697. doi: 10.3390/antiox11040697. Antioxidants (Basel). 2022. PMID: 35453382 Free PMC article. Review.
-
Serum paraoxonase activity, total thiols levels, and oxidative status in patients with acute brucellosis.Wien Klin Wochenschr. 2015 Jun;127(11-12):427-33. doi: 10.1007/s00508-015-0720-z. Epub 2015 Feb 24. Wien Klin Wochenschr. 2015. PMID: 25708067
-
Sex difference: an important issue to consider in epidemiological and clinical studies dealing with serum paraoxonase-1.J Clin Biochem Nutr. 2019 May;64(3):250-256. doi: 10.3164/jcbn.18-73. Epub 2019 Jan 30. J Clin Biochem Nutr. 2019. PMID: 31138960 Free PMC article.
-
Paraoxonase gene polymorphism in south-western Korean population.J Korean Med Sci. 2009 Aug;24(4):561-6. doi: 10.3346/jkms.2009.24.4.561. Epub 2009 Jul 29. J Korean Med Sci. 2009. PMID: 19654933 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous